Share

July 12, 2016; 87 (2) ArticleOpen Access

Cholinergic and perfusion brain networks in Parkinson disease dementia

Sean J. Colloby, Ian G. McKeith, David J. Burn, David J. Wyper, John T. O'Brien, John-Paul Taylor
First published June 15, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002839
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1625

Share

Article Information

vol. 87 no. 2 178-185
DOI: 
https://doi.org/10.1212/WNL.0000000000002839
PubMed: 
27306636
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 28, 2015
  • Accepted in final form March 30, 2016
  • First Published June 15, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Sean J. Colloby, PhD,
    2. Ian G. McKeith, MD,
    3. David J. Burn, MD,
    4. David J. Wyper, PhD,
    5. John T. O'Brien, DM* and
    6. John-Paul Taylor, PhD*
  1. Sean J. Colloby, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ian G. McKeith, MD,
    3. Scientific Advisory Boards:

    1. (1) GE Healthcare (2) Nutricia (3) Axovant Sciences

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) GE Healthcare (2) Nutricia

    Editorial Boards:

    1. (1) Alzheimer's Research and Therapy

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) GE Healthcare

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) GE Healthcare

    Research Support, Government Entities:

    1. (1) NIHR BRC 2012-17 (2) NIHR Dendron 2010-15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David J. Burn, MD,
    4. Scientific Advisory Boards:

    1. Profile Pharma - Chairing one panel on safinamide in UK (2016)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Acadia Pharmaceuticals: speaker honorarium at Movement Disorders Meeting in San Diego 2015

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Henry Stewart publishers for online movement disorders resource Oxford University Press for Editing

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. BIAL - payment to University (not personal)in 2015

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. A Biomedical Research Unit in Lewy Body Dementia. NIHR: 1st April 2012 - 31st March 2017; (Burn DJ, McKeith IG, O?Brien JT, Kirkwood TBL, Chinnery PF, Ford GA).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Parkinson's UK: Visual symptoms in Parkinson?s disease and Parkinson?s disease dementia: Association with ocular and retinal pathology, visuo-perceptual deficits and impact on daily living and quality of life. Parkinson?s UK: November 2007- October 2010; (Archibald N, Mosimann UP, Clarke MP, Burn DJ). Predicting Dementia in Parkinson?s disease: A genotypic and phenotypic study (ICICLE-PD). Parkinson?s UK REF J0802, UK: October 2007 ? September 2012; (Burn DJ, Barker RA, Brooks DJ, O?Brien JT, McKeith IG, Chinnery PF, Owen AM, Brayne CEG, Robbins T, Sawcer S, Coleman S). The Parkinson?s Repository of Biomarkers and Networked Datasets (PROBAND) programme: A UK national clinical consortium linking novel biomarker research to clinical expression, and progression rates, in Parkinson?s disease. Parkinson?s UK: 2011-2015; (Grosset D, Burn DJ, Barker RA, Ben-Shlomo Y, Bajaj N, Hardy J, Wood NW, Morris HR). Apomorphine: A modifier of amyloid deposition in Parkinson?s disease? Parkinson?s UK REF K-1101: October 2011 - April 2012;(Burn DJ, Revesz T, Lees AJ). Michael J Fox Foundation Clinical trial to compare cognitive scales. Michael J Fox Foundation: 1st October 2011 - 30th September 2016; (Burn DJ, Weintraub D). Predicting cognitive profiles in Parkinson?s disease: A multimodal approach. Michael J Fox Foundation: 1st November 2011 - 31st October 2013; (Burn DJ, Rochester L, O?Brien JT, Coleman SY, Baker MR).

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. David J. Wyper, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. John T. O'Brien, DM* and
    6. Scientific Advisory Boards:

    1. (1) TAURx (2) Cytox

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Pfizer, speaker honoraria (2) GE Healthcare, speaker honoraria (3) Eisai, speaker honoraria (4) Shire, speaker honoraria (5) Lundbeck, speaker honoraria (6) Lilly, speaker honoraria (7) Novartis, speaker honoraria

    Editorial Boards:

    1. (1) Psychological Medicine, Editorial Board (2) International Psychogeriatrics, Deputy Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) GE Healthcare (2) Bayer Healthcare (3) Lilly

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Lilly

    Research Support, Government Entities:

    1. (1) Parkinson?s Disease Society 01.10.2007-30.09.2010; (2) Sir Jules Thorn Charitable Trust, 01.02.2006- 31.01.2011; (3) DoH/Wellcome Trust, 01.06.2006-31.05.2011; (4) Medical Research Council, 01.11.2007-31.12.2013; (5) Parkinson's Disease Society, 01.02.2009-31.01.2014; (6) Member of the NIHR College of Senior Investigators, 01.04.2009-31.03.2014; (7) NIHR, 01.03.2010-28.02.2013; (8) Wellcome Trust Intermediate Fellowship, 01.05.2010- 30.04.2013; (9) NIHR-RfPB, 01.08.2010-31.07.2012. (10) The Food Standards Agency, 01.12.2010-31.07.2013. (11) BUPA/Alzheimer's Society, 01.12.2010-30.11.2012. (12) British Heart Foundation/The Stroke Association, 01.01.2011-31.12.2015. (13) HTA, 01.03.2011-30.04.2014. (14) Alzheimer's Research Trust, 01.03.2011-31.08.2012.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. John-Paul Taylor, PhD*
    7. Scientific Advisory Boards:

    1. (1)Scientific Advisor to Lewy body Society - non-profit entity (2)Cognition Advisory Group (Michael J Fox Foundation) - non-profit entity

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) GE Healthcare, speaker honoraria (2) Flynn Pharmaceuticals, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Consultant for Mentis Cura

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Institute of Health Research (NIHR), United Kingdom, Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University, and an NIHR Biomedical Research Centre award to Newcastle University, support for study (2012-2017). (2)National Institute of Health Research (NIHR) Programme Grant Diamond Lewy, SHAPED and PROVIDE studies, no relationship to current study.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Wellcome Trust, Intermediate Clinical Fellowship (2010-2014), support to last author (Taylor) (2) Alzheimer's Research UK (2011-2014), no relationship to present study (3) Alzheimer's Society UK (2015-2018), no relationship to present study

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute of Neuroscience (S.J.C., I.G.M., D.J.B., J.-P.T.), Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne; SINAPSE (D.J.W.), Institute of Neuroscience and Psychology, University of Glasgow; and Department of Psychiatry (J.T.O.), University of Cambridge, UK.
  1. Correspondence to Dr. Colloby: sean.colloby{at}ncl.ac.uk

Article usage

Article usage: June 2016 to November 2023

AbstractFullPdfSource
Jun 20166430142Highwire
Jul 2016120660228Highwire
Jul 20160167pmc
Aug 20162483649Highwire
Aug 201603013pmc
Sep 2016981530Highwire
Sep 201602216pmc
Oct 2016801818Highwire
Oct 201603812pmc
Nov 201676733Highwire
Nov 201603412pmc
Dec 201659911Highwire
Dec 201602314pmc
Jan 2017621210Highwire
Jan 20170209pmc
Feb 20171152322Highwire
Feb 20170197pmc
Mar 2017503418Highwire
Mar 20170156pmc
Apr 2017561013Highwire
Apr 2017887pmc
May 2017681016Highwire
May 2017111915pmc
Jun 2017461211Highwire
Jun 201741117pmc
Jul 2017221113Highwire
Jul 201741115pmc
Aug 2017241013Highwire
Aug 201781212pmc
Sep 201720418Highwire
Sep 201751420pmc
Oct 2017161316Highwire
Oct 201761214pmc
Nov 201722721Highwire
Nov 2017588pmc
Dec 20170104Highwire
Jan 20188413Highwire
Feb 201812178Highwire
Mar 201810218Highwire
Apr 20183259Highwire
Apr 20182810pmc
May 2018173310Highwire
Jun 20187118Highwire
Jun 2018488pmc
Jul 20185179Highwire
Aug 20186148Highwire
Aug 201801010pmc
Sep 20185124Highwire
Oct 201810234Highwire
Nov 20183165Highwire
Dec 20189117Highwire
Jan 20197143Highwire
Feb 201920129Highwire
Mar 20196209Highwire
Apr 20199318Highwire
May 2019102410Highwire
Jun 20198154Highwire
Jul 20193127Highwire
Aug 201991513Highwire
Sep 20195115Highwire
Oct 201920228Highwire
Nov 201910195Highwire
Dec 201991510Highwire
Jan 202063110Highwire
Feb 2020301322Highwire
Mar 202062214Highwire
Apr 202043023Highwire
May 202061117Highwire
Jun 202061619Highwire
Jul 2020591Highwire
Aug 202011812Highwire
Sep 2020561Highwire
Oct 202051211Highwire
Nov 202082611Highwire
Dec 202012148Highwire
Jan 2021101414Highwire
Feb 2021977Highwire
Mar 202191815Highwire
Apr 20215135Highwire
May 202171514Highwire
Jun 20216114Highwire
Jul 20216119Highwire
Aug 202151510Highwire
Sep 202191610Highwire
Oct 202162224Highwire
Nov 202181828Highwire
Dec 20210215Highwire
Jan 202232010Highwire
Feb 202271812Highwire
Mar 20221219Highwire
Apr 202201713Highwire
May 202251612Highwire
Jun 202261211Highwire
Jul 202211813Highwire
Aug 202252112Highwire
Sep 202231815Highwire
Oct 2022687Highwire
Nov 202222518Highwire
Dec 20221141Highwire
Jan 202323611Highwire
Feb 20233218Highwire
Mar 202331610Highwire
Apr 202341212Highwire
May 2023286Highwire
Jun 202321111Highwire
Jul 2023395Highwire
Aug 202372210Highwire
Sep 20237118Highwire
Oct 20236309Highwire
Nov 202351136Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles